|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Reneo Pharmaceuticals, Inc. (RPHM) |
|
|
$1.70 0.00 (0.00%) as of 4:30 Wed 6/5
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
33,810,000 |
Market
Cap: |
57.48(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.34 - $8.93 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Reneo Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate. Co.'s primary product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta. Co. is developing REN001 in rare genetic diseases that typically present with myopathy and have high unmet medical needs, including primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
414,281 |
414,281 |
414,281 |
554,036 |
Total Buy Value |
$639,578 |
$639,578 |
$639,578 |
$1,688,270 |
Total People Bought |
1 |
1 |
1 |
3 |
Total Buy Transactions |
1 |
1 |
1 |
8 |
Total Shares Sold |
0 |
0 |
115,625 |
115,625 |
Total Sell Value |
$0 |
$0 |
$807,798 |
$807,798 |
Total People Sold |
0 |
0 |
2 |
2 |
Total Sell Transactions |
0 |
0 |
2 |
2 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Muralidhar Bali |
Director |
|
2021-07-14 |
4 |
B |
$8.50 |
$949,756 |
I/I |
111,736 |
2,073,957 |
2.1 |
-10% |
|
Johnson Wendy S. |
Chief Development Officer |
|
2021-07-14 |
4 |
S |
$8.50 |
$949,756 |
D/D |
(111,736) |
0 |
|
10% |
|
Johnson Wendy S. |
Chief Development Officer |
|
2021-07-08 |
4 |
OE |
$1.97 |
$220,120 |
D/D |
111,736 |
111,736 |
|
- |
|
Muralidhar Bali |
Director |
|
2021-06-23 |
4 |
B |
$9.28 |
$192,245 |
I/I |
20,710 |
1,962,221 |
2.1 |
-32% |
|
Muralidhar Bali |
Director |
|
2021-06-22 |
4 |
B |
$8.72 |
$127,487 |
I/I |
14,615 |
1,941,511 |
2.1 |
-29% |
|
Muralidhar Bali |
Director |
|
2021-06-21 |
4 |
B |
$9.03 |
$294,927 |
I/I |
32,659 |
1,926,896 |
2.1 |
-25% |
|
Muralidhar Bali |
Director |
|
2021-06-08 |
4 |
B |
$9.50 |
$157,709 |
I/I |
16,605 |
1,894,237 |
2.1 |
-31% |
|
Muralidhar Bali |
Director |
|
2021-06-04 |
4 |
B |
$9.42 |
$2,422 |
I/I |
257 |
1,877,632 |
2.02 |
-31% |
|
Muralidhar Bali |
Director |
|
2021-06-03 |
4 |
B |
$9.25 |
$111,943 |
I/I |
12,100 |
1,877,375 |
2.1 |
-30% |
|
Muralidhar Bali |
Director |
|
2021-05-28 |
4 |
B |
$9.50 |
$133 |
I/I |
14 |
1,865,275 |
2.02 |
-37% |
|
Muralidhar Bali |
Director |
|
2021-05-27 |
4 |
B |
$9.26 |
$10,369 |
I/I |
1,120 |
1,865,261 |
2.1 |
-34% |
|
Muralidhar Bali |
Director |
|
2021-05-26 |
4 |
B |
$9.38 |
$55,495 |
I/I |
5,915 |
1,864,141 |
2.1 |
-28% |
|
Muralidhar Bali |
Director |
|
2021-04-13 |
4 |
B |
$15.00 |
$3,000,000 |
I/I |
200,000 |
1,858,226 |
2.1 |
-36% |
|
Muralidhar Bali |
Director |
|
2021-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
1,658,226 |
1,658,226 |
|
- |
|
Grey Michael G |
Executive Chairman |
|
2021-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
20,162 |
444,762 |
|
- |
|
Odonnell Niall |
Director |
|
2021-04-13 |
4 |
B |
$15.00 |
$3,000,000 |
I/I |
200,000 |
2,063,713 |
2.1 |
-36% |
|
Odonnell Niall |
Director |
|
2021-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
1,863,713 |
1,863,713 |
|
- |
|
Sonsini Peter W. |
10% Owner |
|
2021-04-13 |
4 |
B |
$15.00 |
$9,999,990 |
D/D |
666,666 |
4,785,494 |
2.45 |
-36% |
|
Sonsini Peter W. |
10% Owner |
|
2021-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
4,118,828 |
4,118,828 |
|
- |
|
Novo A/s |
10% Owner |
|
2021-04-13 |
4 |
B |
$15.00 |
$9,999,990 |
D/D |
666,666 |
3,430,377 |
2.45 |
-36% |
|
Novo A/s |
10% Owner |
|
2021-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,763,711 |
2,763,711 |
|
- |
|
Rivervest Venture Fund Iv, L.p. |
10% Owner |
|
2021-04-09 |
4 |
B |
$15.00 |
$3,000,000 |
I/I |
200,000 |
2,409,220 |
1.5 |
- |
|
Rivervest Venture Fund Iv, L.p. |
10% Owner |
|
2021-04-09 |
4 |
A |
$0.00 |
$0 |
I/I |
1,929,878 |
2,209,220 |
|
- |
|
Grey Michael G |
Executive ChairmanOfficer |
|
2021-04-08 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
424,600 |
|
- |
|
Dorenbaum Alejandro |
Chief Medical OfficerOfficer |
|
2021-04-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,348 |
|
- |
|
52 Records found
|
|
Page 2 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|